Highlights Access Bio, Inc.

Equities

A950130

KR8840090003

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
6,620 ^KRW	+1.38%		-0.30%	-26.20%

2023	Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc.	CI
2023	Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc.	23-09-11	CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	23-05-26	CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	23-05-26	CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	23-05-26	CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	23-05-26	CI
Access Bio, Inc. agreed to acquire Belight Investment for approximately KRW 130 billion.	23-05-25	CI
Access Bio, Inc's Equity Buyback announced on March 24, 2022, has expired with 1,840,483 shares, representing 5.22% for KRW 29,899.64 million.	23-05-22	CI
Access Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
Access Bio, Inc.'s Equity Buyback Plan Extended till May 23, 2023.	23-02-21	CI
AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency; BOS Up 2.6%	22-12-28	MT
AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency	22-12-28	MT
AirBoss of America Brief: Defense Logistics Agency has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at up to US$410 Million to Access Bio	22-12-28	MT
AirBoss of America Brief: AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency	22-12-28	MT
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	22-06-27	CI
Access Bio, Inc. announces an Equity Buyback for KRW 30,000 million worth of its shares.	22-03-24	CI
Access Bio, Inc. authorizes a Buyback Plan.	22-03-23	CI
Atomo Diagnostics Limited and Access Bio, Inc. Renegotiate Supply Agreements	21-10-04	CI
Vivera Pharmaceuticals Partners with Areum Bio LLC and Access Bio, Inc. to Expand the National Distribution of Emergency Use Authorized COVID-19 Rapid Tests	21-06-30	CI
Atomo Diagnostics Limited Receives FDA Clearance for Covid-19 Antibody Test	21-06-27	CI
Intrivo Diagnostics Secures National Distribution Agreement with McKesson Medical-Surgical for Access Bio CareStart™ COVID-19 Tests	20-12-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Access Bio, Inc.

Equities

A950130

KR8840090003

Highlights

Filters